Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds


Theralase Technologies Inc. recently announced the company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course.

The patent, titled Metal-Based Thiophene Photodynamic Compounds and Their Use, advances Theralase’s intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (ACT) platform. The patent encompasses an extensive library of PDCs, including Theralase’s lead PDC, TLD-1433, approved by Health Canada to be evaluated in a Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study (Study II). Currently, Study II has successfully been launched in 3 Canadian clinical oncology sites with 2 patients treated. The company has submitted a Food and Drug Administration (FDA) Investigational New Drug (IND) application and is currently working with the FDA in the approval of the IND to allow the Company to launch clinical Study II sites in the US.

Dr. Arkady Mandel MD, PhD, DSc, Chief Scientific Officer of Theralase, said “The latest European Patent reinforces the intrinsic value of our PDC anti-cancer technology and confirms the highly innovative nature of them and their inherent ability to destroy cancer. This patent provides the company intellectual property protection for its PDC technology until mid-2032 and it complements the already robust set of 9 patent families securing the protection of Theralase’s PDCs and related ACT. This European patent protects our lead PDC compound, TLD-1433, in addition to the Canadian and US patent already issued on this innovative technology. The new patent also provides us with intellectual property to commercialize this PDC technology in Europe.”

The European Union market is the second largest economy in the world in nominal terms after the United States. Global spending on cancer medicines continues to rise with therapeutic and supportive care use at $133 billion globally in 2017, up from $96 billion in 2013. Overall, the global market for oncology therapeutic medicines will reach as much as $200 billion by 2022, averaging 10%-13% growth over the next 5 years, with the US market reaching as much as $100 billion by 2022, averaging 12%-15% annual growth.

It is estimated that there will be 141,000 new cases of bladder cancer in Europe by 2020. Additionally, it is projected that there will be approximately 42,000 deaths in Europe caused by bladder cancer in 2019, approximately 31,080 men and 10,833 women.

Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. For mor einformation, visit www.theralase.com and www.sedar.com.

Share This